Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.52 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.52 |
| ▸ | APLNR | P35414 | 1/20 | 0.49 |
| ▸ | NTMT1 | Q9BV86 | 2/20 | 0.46 |
| ▸ | MMP1 | P03956 | 1/20 | 0.46 |
| ▸ | MMP3 | P08254 | 1/20 | 0.46 |
| ▸ | ITGB3 | P05106 | 3/20 | 0.45 |
| ▸ | ITGA2B | P08514 | 3/20 | 0.45 |
| ▸ | F2 | P00734 | 1/20 | 0.44 |
| ▸ | NMT1 | P30419 | 5/20 | 0.43 |
| ▸ | NMT2 | O60551 | 4/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19681207 | 0.95 | MMP3 (0.46) | SIRT6SIRT1APLNRNTMT1MMP1 | |
| SCHEMBL19685411 | 0.92 | APLNR (0.48) | SIRT6SIRT1APLNRNTMT1MMP1 | |
| SCHEMBL19681264 | 0.91 | POLB (0.44) | SIRT6SIRT1APLNRNTMT1MMP1 | |
| SCHEMBL19681283 | 0.91 | APLNR (0.44) | SIRT6SIRT1APLNRNTMT1MMP1 | |
| SCHEMBL21166938 | 0.91 | MMP1 (0.53) | APLNRNTMT1MMP1MMP3ITGB3 | |
| SCHEMBL21705592 | 0.89 | MMP3 (0.47) | SIRT6SIRT1APLNRMMP1MMP3 | |
| SCHEMBL21351094 | 0.88 | MMP3 (0.46) | SIRT6SIRT1APLNRNTMT1MMP1 | |
| SCHEMBL19677790 | 0.87 | SIRT6 (0.53) | SIRT6SIRT1APLNRNTMT1F2 | |
| SCHEMBL20370188 | 0.87 | MMP3 (0.46) | APLNRMMP1MMP3F2NPSR1 | |
| SCHEMBL21705523 | 0.87 | APLNR (0.53) | SIRT6SIRT1APLNRNTMT1MMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11707507-B2 | Compositions in the form of an injectable aqueous solution comprising amylin, an amylin receptor agonist or an amylin analog, and a co-polyamino acid | ADOCIA (FR) | 2023-07-25 | — | — | US | disclosed |
| US-20200306346-A1 | COMPOSITIONS IN THE FORM OF AN INJECTABLE AQUEOUS SOLUTION COMPRISING HUMAN GLUCAGON AND A CO-POLYAMINO ACID | ADOCIA (FR) | 2020-10-01 | — | — | US | disclosed |
| US-20200046805-A1 | COMPOSITIONS IN THE FORM OF AN INJECTABLE AQUEOUS SOLUTION COMPRISING AMYLIN, AN AMYLIN RECEPTOR AGONIST OR AN AMYLIN ANALOG, AND A CO-POLYAMINO ACID | ADOCIA (FR) | 2020-02-13 | — | — | US | disclosed |
| US-10548952-B2 | Injectable solution at pH7 comprising at least one basal insulin the pI of which is from 5.8 to 8.5, a prandial insulin and/or a gastrointestinal hormone, and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals | ADOCIA (FR) | 2020-02-04 | — | — | US | disclosed |
| US-10463717-B2 | Compositions in the form of an injectable aqueous solution comprising amylin, an amylin receptor agonist or an amylin analog, and a co-polyamino acid | ADOCIA (FR) | 2019-11-05 | — | — | US | disclosed |
| US-20190274953-A1 | PH 7 INJECTABLE SOLUTION COMPRISING AT LEAST ONE BASIC INSULIN WITH A PI COMPRISED FROM 5.8 TO 8.5 AND A CO-POLYAMINOACIDE BEARING CARBOXYLATE CHARGES AND HYDROPHOBIC RADICALS | ADOCIA (FR) | 2019-09-12 | — | — | US | disclosed |
| US-20190275110-A1 | COMPOSITIONS IN THE FORM OF AN INJECTALE AQUEOUS SOLUTION COMPRISING HUMAN GLUCAGON AND A CO-POLYAMINO ACID | ADOCIA (FR) | 2019-09-12 | — | — | US | disclosed |
| US-20190275108-A1 | COMPOSITIONS IN THE FORM OF AN INJECTABLE AQUEOUS SOLUTION COMPRISING AMYLIN, AN AMYLIN RECEPTOR AGONIST OR AN AMYLIN ANALOGUE AND A CO-POLYAMINO ACID | ADOCIA (FR) | 2019-09-12 | — | — | US | disclosed |
| US-10383918-B2 | Compositions in the form of an injectable aqueous solution comprising human glucagon and a statistical co-polyamino acid | ADOCIA (FR) | 2019-08-20 | — | — | US | disclosed |
| US-10383920-B2 | Injectable solution at pH 7 comprising at least one basal insulin the pI of which is from 5.8 to 8.5 and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals | ADOCIA (FR) | 2019-08-20 | — | — | US | disclosed |
| US-20180193421-A1 | COMPOSITIONS IN THE FORM OF AN INJECTABLE AQUEOUS SOLUTION COMPRISING AMYLIN, AN AMYLIN RECEPTOR AGONIST OR AN AMYLIN ANALOG, AND A CO-POLYAMINO ACID | ADOCIA (FR) | 2018-07-12 | — | — | US | disclosed |
| US-20170348395-A1 | Compositions in the form of an injectable aqueous solution comprising human glucagon and a co-polyamino acid | ADOCIA (FR) | 2017-12-07 | — | — | US | disclosed |
| US-20170348423-A1 | Injectable solution at pH 7 comprising at least one basal insulin the pl of which is from 5.8 to 8.5 and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals | ADOCIA (FR) | 2017-12-07 | — | — | US | disclosed |
| US-20170348394-A1 | COMPOSITIONS IN THE FORM OF AN INJECTABLE AQUEOUS SOLUTION COMPRISING HUMAN GLUCAGON AND A STATISTICAL CO-POLYAMINO ACID | ADOCIA (FR) | 2017-12-07 | — | — | US | disclosed |
| US-20170348396-A1 | Injectable solution at pH7 comprising at least one basal insulin the pI of which is from 5.8 to 8.5, a prandial insulin and/or a gastrointestinal hormone, and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals | ADOCIA (FR) | 2017-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190275108-A1 | COMPOSITIONS IN THE FORM OF AN INJECTABLE AQUEOUS SOLUTION COMPRISING AMYLIN, AN AMYLIN RECEPTOR AGONIST OR AN AMYLIN ANALOGUE AND A CO-POLYAMINO ACID | IAPP, GPR119, GLP1R | SIRT6 3597/4885SIRT1 3522/4885APLNR 18/4885 |
| US-20180193421-A1 | COMPOSITIONS IN THE FORM OF AN INJECTABLE AQUEOUS SOLUTION COMPRISING AMYLIN, AN AMYLIN RECEPTOR AGONIST OR AN AMYLIN ANALOG, AND A CO-POLYAMINO ACID | IAPP, GPR119, GIPR | SIRT6 3619/4885SIRT1 3630/4885APLNR 16/4885 |
| US-10463717-B2 | Compositions in the form of an injectable aqueous solution comprising amylin, an amylin receptor agonist or an amylin analog, and a co-polyamino acid | IAPP, GPR119, GIPR | SIRT6 3364/4885SIRT1 3563/4885APLNR 21/4885 |
| US-20200306346-A1 | COMPOSITIONS IN THE FORM OF AN INJECTABLE AQUEOUS SOLUTION COMPRISING HUMAN GLUCAGON AND A CO-POLYAMINO ACID | GCG, GLP1R, GCGR | SIRT6 753/4885SIRT1 1383/4885APLNR 543/4885 |
| US-20200046805-A1 | COMPOSITIONS IN THE FORM OF AN INJECTABLE AQUEOUS SOLUTION COMPRISING AMYLIN, AN AMYLIN RECEPTOR AGONIST OR AN AMYLIN ANALOG, AND A CO-POLYAMINO ACID | IAPP, INSR, GLP1R | SIRT6 3723/4885SIRT1 3437/4885APLNR 23/4885 |
| US-20170348423-A1 | Injectable solution at pH 7 comprising at least one basal insulin the pl of which is from 5.8 to 8.5 and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals | IAPP, IDE, INSR | SIRT6 3384/4885SIRT1 4244/4885APLNR 1847/4885 |
| US-20170348394-A1 | COMPOSITIONS IN THE FORM OF AN INJECTABLE AQUEOUS SOLUTION COMPRISING HUMAN GLUCAGON AND A STATISTICAL CO-POLYAMINO ACID | GCG, GLP1R, IAPP | SIRT6 844/4885SIRT1 1823/4885APLNR 662/4885 |
| US-10383918-B2 | Compositions in the form of an injectable aqueous solution comprising human glucagon and a statistical co-polyamino acid | GCG, GLP1R, IAPP | SIRT6 844/4885SIRT1 1823/4885APLNR 662/4885 |
| US-20190275110-A1 | COMPOSITIONS IN THE FORM OF AN INJECTALE AQUEOUS SOLUTION COMPRISING HUMAN GLUCAGON AND A CO-POLYAMINO ACID | GCG, GLP1R, IAPP | SIRT6 913/4885SIRT1 1775/4885APLNR 520/4885 |
| US-20170348395-A1 | Compositions in the form of an injectable aqueous solution comprising human glucagon and a co-polyamino acid | GCG, GLP1R, IAPP | SIRT6 1034/4885SIRT1 1847/4885APLNR 671/4885 |
| US-11707507-B2 | Compositions in the form of an injectable aqueous solution comprising amylin, an amylin receptor agonist or an amylin analog, and a co-polyamino acid | IAPP, INSR, GLP1R | SIRT6 3723/4885SIRT1 3437/4885APLNR 23/4885 |
| US-10383920-B2 | Injectable solution at pH 7 comprising at least one basal insulin the pI of which is from 5.8 to 8.5 and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals | IAPP, IDE, INSR | SIRT6 3177/4885SIRT1 4225/4885APLNR 2130/4885 |
| US-20170348396-A1 | Injectable solution at pH7 comprising at least one basal insulin the pI of which is from 5.8 to 8.5, a prandial insulin and/or a gastrointestinal hormone, and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals | IAPP, F7, GIPR | SIRT6 2765/4885SIRT1 3926/4885APLNR 1129/4885 |
| US-20190274953-A1 | PH 7 INJECTABLE SOLUTION COMPRISING AT LEAST ONE BASIC INSULIN WITH A PI COMPRISED FROM 5.8 TO 8.5 AND A CO-POLYAMINOACIDE BEARING CARBOXYLATE CHARGES AND HYDROPHOBIC RADICALS | GPR119, INSR, GCG | SIRT6 1258/4885SIRT1 3037/4885APLNR 389/4885 |
| US-10548952-B2 | Injectable solution at pH7 comprising at least one basal insulin the pI of which is from 5.8 to 8.5, a prandial insulin and/or a gastrointestinal hormone, and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals | IAPP, F7, GIPR | SIRT6 2765/4885SIRT1 3926/4885APLNR 1129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.